In this review:
Endocrine therapy ± ribociclib: MONOLEESA-7 OS results
Neratinib + capecitabine in pretreated HER2+ MBC
Extended letrozole after sequential endocrine therapy
Exemestane-based regimen vs capecitabine in premenopausal HR+ MBC
Safety of pregnancy post-breast cancer in BRCA carriers
Genomic alterations in MBC resistant to CDK4/6 inhibitors
Genomic analysis identifies early progression in ER+ advanced disease
Low-fat dietary pattern and long-term breast cancer risk
Considering PBI vs WBI: PROs from NSABP B-39/RTOG 0413
Please login below to download this issue (PDF)